{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T06:31:49Z","timestamp":1648967509204},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:p>This commentary reviews the novel mechanism of action of TRC105 in the context of treatments currently available for metastatic renal cell carcinoma, highlighting the recent findings of Choueiri and colleagues.<\/jats:p>","DOI":"10.1634\/theoncologist.2018-0443","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T15:05:12Z","timestamp":1535036712000},"page":"143-145","source":"Crossref","is-referenced-by-count":3,"title":["Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome"],"prefix":"10.1093","volume":"24","author":[{"given":"Andrew W.","family":"Hahn","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"2021122506214190900_onco12693-bib-0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2021122506214190900_onco12693-bib-0002","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/01.ju.0000132126.85812.7d","article-title":"Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy","volume":"172","author":"Stephenson","year":"2004","journal-title":"J Urol"},{"key":"2021122506214190900_onco12693-bib-0003","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/EDBK_174469","article-title":"Evolving treatment paradigm in metastatic renal cell carcinoma","volume":"37","author":"Gill","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2021122506214190900_onco12693-bib-0004","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"Rini","year":"2009","journal-title":"Lancet"},{"key":"2021122506214190900_onco12693-bib-0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J. Clin Oncol"},{"key":"2021122506214190900_onco12693-bib-0006","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/156720111793663570","article-title":"Endoglin-targeted cancer therapy","volume":"8","author":"Seon","year":"2011","journal-title":"Curr Drug Deliv"},{"key":"2021122506214190900_onco12693-bib-0007","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11912-013-0365-x","article-title":"Endoglin for targeted cancer treatment","volume":"16","author":"Rosen","year":"2014","journal-title":"Curr Oncol Rep"},{"key":"2021122506214190900_onco12693-bib-0008","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.284.5419.1534","article-title":"Defective angiogenesis in mice lacking endoglin","volume":"284","author":"Li","year":"1999","journal-title":"Science"},{"key":"2021122506214190900_onco12693-bib-0009","doi-asserted-by":"crossref","first-page":"e50920","DOI":"10.1371\/journal.pone.0050920","article-title":"Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies","volume":"7","author":"Nolan-Stevaux","year":"2012","journal-title":"PLoS One"},{"key":"2021122506214190900_onco12693-bib-0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1634\/theoncologist.2018-0299","article-title":"An open label phase 1b dose escalation study of TRC105 (anti-endoglin antibody) with axitinib in patients with renal cell carcinoma","volume":"24","author":"Choueiri","year":"2019","journal-title":"The Oncologist"},{"key":"2021122506214190900_onco12693-bib-0011","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122506214190900_onco12693-bib-0012","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1002\/cncr.30942","article-title":"Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer","volume":"123","author":"Dorff","year":"2017","journal-title":"Cancer"},{"key":"2021122506214190900_onco12693-bib-0013","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1158\/1078-0432.CCR-16-2395","article-title":"The DART study: Results from the dose-escalation and expansion cohorts evaluating the combination of dalantercept plus axitinib in advanced renal cell carcinoma","volume":"23","author":"Voss","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122506214190900_onco12693-bib-0014","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122506214190900_onco12693-bib-0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0443","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/2\/143\/41917113\/oncolo_24_2_143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/2\/143\/41917113\/oncolo_24_2_143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:22:04Z","timestamp":1640413324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/2\/143\/6439076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,8,23]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0443","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2,1]]},"published":{"date-parts":[[2018,8,23]]}}}